You are not currently logged in.
Access your personal account or get JSTOR access through your library or other institution:
If You Use a Screen ReaderThis content is available through Read Online (Free) program, which relies on page scans. Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
TRIPS: Its Possible Impact on Biotech Segment of the Indian Pharmaceutical Industry
Shyama V. Ramani and Augustin Maria
Economic and Political Weekly
Vol. 40, No. 7 (Feb. 12-18, 2005), pp. 675-683
Published by: Economic and Political Weekly
Stable URL: http://www.jstor.org/stable/4416206
Page Count: 9
Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
Preview not available
Many countries of the world, including India, have achieved self-sufficiency in knowledge intensive sectors by allowing for a loosely defined intellectual property rights (IPR) regime. The implementation of TRIPS worldwide represents a step in the opposite direction and its impact on the production and innovative capacity of developing countries in knowledge intensive sectors is not at all clear. Taking India as representative of a technologically advanced developing country, and the biotech based segment of the pharmaceutical industry as an example of an emerging knowledge intensive sector, we examine the possible impact of TRIPS on the incentives and ability to innovate. The conclusion is that TRIPS is not likely to have a significant impact on incentives for innovation creation in the biotech segment.
Economic and Political Weekly © 2005 Economic and Political Weekly